BMRN Stock Forecast: BioMarin Pharmaceutical, Inc. Price Predictions for 2026-2027
The 28 Wall Street analysts covering BioMarin Pharmaceutical, Inc. hold a median 12-month price target of $89 — +47.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 51 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores BioMarin Pharmaceutical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Issuance (20): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
BMRN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BMRN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +47.3% from it.
Of the 20 most recent actions, 7 moved their price target up and 9 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2026 | Morgan Stanley | Maintains | Overweight | $119 → $103 |
| 4 Nov 2026 | JP Morgan | Maintains | Overweight | $87 → $86 |
| 3 Nov 2026 | HC Wainwright & Co. | Reiterates | Neutral | $60 |
| 3 Nov 2026 | Morgan Stanley | Maintains | Overweight | $122 → $119 |
| 3 Nov 2026 | Oppenheimer | Maintains | Outperform | $97 → $94 |
| 3 Nov 2026 | RBC Capital | Maintains | Sector Perform | $62 → $60 |
| 3 Nov 2026 | Stifel | Maintains | Hold | $70 → $66 |
| 21 Oct 2026 | Morgan Stanley | Maintains | Overweight | $124 → $122 |
| 20 Oct 2026 | Cantor Fitzgerald | Reiterates | Overweight | $86 |
| 20 Oct 2026 | JP Morgan | Maintains | Overweight | $86 → $87 |
| 15 Oct 2026 | UBS | Assumes | Buy | $114 → $88 |
| 14 Oct 2026 | Barclays | Maintains | Overweight | $111 → $114 |
| 10 Sept 2026 | HC Wainwright & Co. | Reiterates | Neutral | $60 |
| 1 Sept 2026 | Piper Sandler | Maintains | Overweight | $88 → $90 |
| 31 Aug 2026 | HC Wainwright & Co. | Maintains | Neutral | $59 → $60 |
| 31 Aug 2026 | Jefferies | Maintains | Buy | $104 → $105 |
| 19 Aug 2026 | BMO Capital | Initiates | Outperform | $98 |
| 18 Aug 2026 | HC Wainwright & Co. | Maintains | Neutral | $60 → $59 |
| 17 Aug 2026 | Barclays | Maintains | Overweight | $105 → $111 |
| 17 Aug 2026 | Piper Sandler | Maintains | Overweight | $82 → $88 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BMRN.
This page is one stock. Monday covers all of them.
BMRN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
BMRN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, BioMarin Pharmaceutical, Inc. returned +15.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
BMRN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 3.3×
- Price / book
- 1.9×
- EV / EBITDA
- 18.0×
Cheaper than 33% of US stocks
Cheaper than 45% of US stocks
Cheaper than 24% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 79.5%
- Operating margin
- 16.3%
- Net margin
- −0.5%
Higher than 90% of US stocks
Higher than 74% of US stocks
Higher than 30% of US stocks
- Return on equity
- −0.3%
- Return on assets
- 3.9%
- Dividend yield
- —
Higher than 44% of US stocks
Higher than 70% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
BioMarin Pharmaceutical, Inc. has a market value of $11.9B and an enterprise value of $15.4B.
Revenue in the twelve months to 30 June 2026: $3.4B. The latest quarter grew 19.9% year on year.
Net income over the same four quarters: $73.0M, a 2.1% net margin.
Diluted earnings per share, trailing twelve months: $0.37.
Free cash flow in the twelve months to 30 June 2026: $725.1M.
forward P/E: 9.8× — the forward figure prices analyst consensus estimates, not reported earnings.
BioMarin Pharmaceutical, Inc. employs 3,221 people — $1.1M of revenue per employee.
Data provided by Twelve Data
BMRN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at BMRN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own BioMarin Pharmaceutical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about BMRN
What is the BMRN stock price forecast for 2026-2027?
The 28 Wall Street analysts covering BioMarin Pharmaceutical, Inc. have a median 12-month price target of $89, with estimates ranging from $60 to $120. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BMRN stock a buy right now?
Of the 28 analysts covering BioMarin Pharmaceutical, Inc., 21 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioMarin Pharmaceutical, Inc. 51 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BMRN?
As at 21 Nov 2026, BioMarin Pharmaceutical, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
Will BMRN stock go up?
No one can know that. What the data says: the median 12-month target from 28 analysts implies +47.3% from the last close, and Ticker Nerd's factor model ranks BioMarin Pharmaceutical, Inc. 51 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BMRN stock forecast for 2030?
No analyst covering BioMarin Pharmaceutical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMRN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $60 to $120 over the next 12 months.
How has BMRN stock performed over the past year?
BioMarin Pharmaceutical, Inc. returned +15.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does BioMarin Pharmaceutical, Inc. do?
BioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing therapies for rare genetic and metabolic diseases. Its portfolio includes approved medicines and advanced treatments such as enzyme replacement therapies, gene therapies, and other specialized biologics designed for patients living with genetically defined conditions.
About BioMarin Pharmaceutical, Inc.
BioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing therapies for rare genetic and metabolic diseases. Its portfolio includes approved medicines and advanced treatments such as enzyme replacement therapies, gene therapies, and other specialized biologics designed for patients living with genetically defined conditions. BioMarin’s products are used in areas including lysosomal storage disorders, achondroplasia, hemophilia, phenylketonuria, and other serious rare diseases. The company serves a specialized role in the healthcare market by addressing conditions that often have limited treatment options, with a business model centered on research, regulatory development, manufacturing, and global commercialization of orphan-disease therapies. Headquartered in San Rafael, California, BioMarin Pharmaceutical Inc. is recognized as a leading rare disease biotechnology company.
CEO Mr. Alexander Hardy · 3,221 employees · United States · https://www.biomarin.com